Molecular imaging in neuroendocrine tumors: Molecular uptake mechanisms and clinical results

110Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.

Abstract

Neuroendocrine tumors can originate almost everywhere in the body and consist of a great variety of subtypes. This paper focuses on molecular imaging methods using nuclear medicine techniques in neuroendocrine tumors, coupling molecular uptake mechanisms of radiotracers with clinical results. A non-systematic review is presented on receptor based and metabolic imaging methods. Receptor-based imaging covers the molecular backgrounds of somatostatin, vaso-intestinal peptide (VIP), bombesin and cholecystokinin (CCK) receptors and their link with nuclear imaging. Imaging methods based on specific metabolic properties include meta-iodo-benzylguanide (MIBG) and dimercapto-sulphuric acid (DMSA-V) scintigraphy as well as more modern positron emission tomography (PET)-based methods using radio-labeled analogues of amino acids, glucose, dihydroxyphenylalanine (DOPA), dopamine and tryptophan. Diagnostic sensitivities are presented for each imaging method and for each neuroendocrine tumor subtype. Finally, a Forest plot analysis of diagnostic performance is presented for each tumor type in order to provide a comprehensive overview for clinical use. © 2009 Elsevier Ireland Ltd. All rights reserved.

Cite

CITATION STYLE

APA

Koopmans, K. P., Neels, O. N., Kema, I. P., Elsinga, P. H., Links, T. P., de Vries, E. G. E., & Jager, P. L. (2009, September). Molecular imaging in neuroendocrine tumors: Molecular uptake mechanisms and clinical results. Critical Reviews in Oncology/Hematology. https://doi.org/10.1016/j.critrevonc.2009.02.009

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free